WO2021146326A3 - Hla peptide ligands from the plasma exosome - Google Patents

Hla peptide ligands from the plasma exosome Download PDF

Info

Publication number
WO2021146326A3
WO2021146326A3 PCT/US2021/013292 US2021013292W WO2021146326A3 WO 2021146326 A3 WO2021146326 A3 WO 2021146326A3 US 2021013292 W US2021013292 W US 2021013292W WO 2021146326 A3 WO2021146326 A3 WO 2021146326A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide ligands
hla
present
cells
hla peptide
Prior art date
Application number
PCT/US2021/013292
Other languages
French (fr)
Other versions
WO2021146326A2 (en
Inventor
Curtis McMURTREY
Saghar KAABINEJADIAN
Original Assignee
Pure Protein Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pure Protein Llc filed Critical Pure Protein Llc
Publication of WO2021146326A2 publication Critical patent/WO2021146326A2/en
Publication of WO2021146326A3 publication Critical patent/WO2021146326A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

HLA protein complexes bind foreign or altered-self peptide ligands and present these peptide ligands on the surface of diseased/infected cells to adaptive T-cells. In addition to being present on the surface of cells, HLA complexes are also present in a soluble form as well as on exosomes found in human plasma. Here we describe a method of isolating HLA complexes in human plasma and identifying peptides bound to such HLA complexes.
PCT/US2021/013292 2020-01-14 2021-01-13 Hla peptide ligands from the plasma exosome WO2021146326A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062960856P 2020-01-14 2020-01-14
US62/960,856 2020-01-14

Publications (2)

Publication Number Publication Date
WO2021146326A2 WO2021146326A2 (en) 2021-07-22
WO2021146326A3 true WO2021146326A3 (en) 2021-08-19

Family

ID=76864270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/013292 WO2021146326A2 (en) 2020-01-14 2021-01-13 Hla peptide ligands from the plasma exosome

Country Status (1)

Country Link
WO (1) WO2021146326A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150140127A1 (en) * 2012-06-26 2015-05-21 Temple University-Of The Commonwealth System Of Higher Education Method for detecting injury to the brain
US20150241431A1 (en) * 2014-02-27 2015-08-27 Board Of Regents, The University Of Texas System Methods and Compositions for Isolating Exosomes
US20160280750A1 (en) * 2013-07-01 2016-09-29 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US20170333541A1 (en) * 2012-08-31 2017-11-23 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150140127A1 (en) * 2012-06-26 2015-05-21 Temple University-Of The Commonwealth System Of Higher Education Method for detecting injury to the brain
US20170333541A1 (en) * 2012-08-31 2017-11-23 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
US20160280750A1 (en) * 2013-07-01 2016-09-29 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US20150241431A1 (en) * 2014-02-27 2015-08-27 Board Of Regents, The University Of Texas System Methods and Compositions for Isolating Exosomes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALAJ ET AL.: "Heparin affinity purification of extracellular vesicles", SCI REP, vol. 5, 2015, pages 10266, XP055286185, DOI: 10.1038/srep10266 *
KONOSHENKO ET AL.: "Isolation of Extracellular Vesicles: General Methodologies and Latest Trends", BIOMED RES INT, vol. 2018, 2018, pages 8545347, XP055548577 *
LI ET AL.: "Progress in Exosome Isolation Techniques", THERANOSTICS, vol. 7, no. 3, 2017, pages 789 - 804, XP055417509, DOI: 10.7150/thno.18133 *
RITZ ET AL.: "High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera", PROTEOMICS, vol. 16, no. 10, 2016, pages 1570 - 1580, XP055848304 *
SYNOWSKY ET AL.: "The major histocompatibility complex class I immunopeptidome of extracellular vesicles", J BIOL CHEM., vol. 292, no. 41, 2017, pages 17084 - 17092, XP055848292 *

Also Published As

Publication number Publication date
WO2021146326A2 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
EP2283869A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
WO2016187508A3 (en) Shared neoantigens
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
WO2007149062A3 (en) Bioactive fus1 peptides and nanoprticle-polypeptide complexes
WO2007073509A8 (en) Modified annexin proteins and methods for their use in organ transplantation
EP2388271A3 (en) Human Antibodies and Proteins
WO2021158619A8 (en) IL-7Rα BINDING COMPOUNDS
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
AU2741897A (en) Suppression of immune response via inhibition of cathepsin s
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
WO2004067555A3 (en) Protein and peptide delivery to mammalian cells in vitro
WO1999050637A8 (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
WO2021146326A3 (en) Hla peptide ligands from the plasma exosome
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
WO2003068800A3 (en) Isolated peptides which bind to hla molecules and uses thereof
EP3974443A3 (en) Peptides derived from melanoma-associated antigen b2 (mageb2)
WO2023205702A3 (en) Modified exosomes and methods of use
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
WO2001023560A3 (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
WO2003064614A3 (en) Transport peptides and uses therefor
WO2008002153A3 (en) Novel polypeptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21740783

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21740783

Country of ref document: EP

Kind code of ref document: A2